BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 27, 2010
View Archived Issues
Bullseye: MacroGenics Back on Target with Double DART Deals
After learning late last week that lead program teplizumab failed to meet its primary endpoint in a Phase III trial for Type 1 diabetes, MacroGenics Inc. President and CEO Scott Koenig was disappointed, but philosophical. (BioWorld Today)
Read More
IDC Signs MedImmune to First Vaccine Adjuvant Partnership
Read More
Ariad Topples 9.5% on Stock Offering to Fund Cancer Drug
Read More
Karo Bio Rakes in $80M for Eprotirome Development
Read More
Amgen Treading Water Ahead of Anticipated Dmab SRE Nod
Read More
Savient Moves on with Gout Drug Launch Despite No Buyer
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Stock Movers
Read More